AstraZeneca Pharma India Limited — Important, 02-09-2025: Disclosure of material issue

AstraZeneca Pharma India (AZPIL) has formally surrendered its manufacturing license, completing its previously announced exit from its manufacturing site.

**Issue & Impact:** This signifies a strategic shift for AZPIL, moving away from direct manufacturing operations. The company's action of surrendering the license (originally valid till Dec 2027) formalizes this transition. For investors, this could mean streamlined operations and reduced fixed costs, with a potential reliance on contract manufacturing or a stronger focus on sales and distribution in India. This move finalizes their strategic repositioning in the market.